East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Potassium Chloride Oral Solution USP, 10% (20 mEq/15 mL) and 20% (40 mEq/15 mL). Aurobindo Pharma’s Potassium Chloride Oral Solution USP, are an AB-rated generic equivalent to the reference listed drug (RLD), Potassium Chloride Oral Solution manufactured by Genus Lifesciences, Inc.

Potassium Chloride Oral Solution are indicated for:

• The treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient.